Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Stephenson

Showing results (221-230 of 241) with videos related to

Pageof 25
Sort By:
Physical Review Letters|May 23, 2006
Polarized proton collisions at 205 GeV at RHICM Bai, T Roser, L Ahrens, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2020
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, et al.
The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Pageof 25

Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Physical Review Letters|May 23, 2006
Polarized proton collisions at 205 GeV at RHICM Bai, T Roser, L Ahrens, et al.
NPJ Vaccines|January 11, 2022
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamstersLisa H Tostanoski, Abishek Chandrashekar, Shivani Patel, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 8, 2020
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, et al.
The Journal of Infectious Diseases|April 19, 2018
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Nature Medicine|May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trialBoris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
Pageof 25